The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit announce a partnership with the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE). The collaboration aims to enhance professional collaborations in the rare disease field. Financial details of the partnership were not disclosed.
Rare Disease Landscape in China
Among the 121 rare diseases included on the Chinese government’s official list, 35 have no available therapy globally, and 9 have no drugs available in China. This significant unmet need underscores the importance of the partnership between Takeda and CCCMHPIE.
Partnership Objectives
The collaboration is expected to accelerate access to rare disease drugs for Chinese patients, improve the supply security of novel rare disease drugs, and potentially lead to changes in regulatory policies. By leveraging Takeda’s expertise in rare disease treatments and CCCMHPIE’s extensive network, the partnership aims to make a meaningful impact on the lives of patients with rare diseases in China.-Fineline Info & Tech
